Moderna, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Moderna, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $19.26B | Feb 24, 2023 |
| FY2022 | Dec 31, 2021 | $18.47B | Feb 24, 2023 |
| FY2022 | Dec 31, 2020 | $803.00M | Feb 24, 2023 |
| FY2019 | Dec 31, 2019 | $14.06M | Feb 27, 2020 |
| FY2019 | Sep 30, 2019 | $17.05M | Feb 27, 2020 |
| FY2019 | Jun 30, 2019 | $13.08M | Feb 27, 2020 |
| FY2019 | Mar 31, 2019 | $16.03M | Feb 27, 2020 |
| FY2019 | Dec 31, 2018 | $35.42M | Feb 27, 2020 |
| FY2019 | Sep 30, 2018 | $41.76M | Feb 27, 2020 |
| FY2019 | Jun 30, 2018 | $28.85M | Feb 27, 2020 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.94B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $3.24B | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $6.85B | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $19.26B | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $18.47B | Feb 23, 2024 |
| FY2019 | Dec 31, 2019 | $60.21M | Feb 27, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.82B) | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | ($3.56B) | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | ($4.71B) | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $8.36B | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $12.20B | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | ($747.00M) | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | ($514.00M) | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | ($384.73M) | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | ($255.92M) | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | ($216.21M) | Mar 13, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.07B) | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | ($3.95B) | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | ($4.24B) | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $9.42B | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $13.30B | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | ($763.00M) | Feb 24, 2023 |
| FY2019 | Dec 31, 2019 | ($130.56M) | Feb 27, 2020 |
| FY2019 | Sep 30, 2019 | ($129.82M) | Feb 27, 2020 |
| FY2019 | Jun 30, 2019 | ($143.71M) | Feb 27, 2020 |
| FY2019 | Mar 31, 2019 | ($141.64M) | Feb 27, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.13B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $4.54B | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $4.85B | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $3.30B | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $1.99B | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $1.37B | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $496.00M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $454.08M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $410.46M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $274.72M | Mar 13, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.87B) | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | ($3.00B) | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | ($3.12B) | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $4.98B | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $13.62B | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $2.03B | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | ($459.00M) | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | ($330.87M) | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | ($331.48M) | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $66.73M | Mar 13, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $192.00M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $1.05B | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $707.00M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $400.00M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $284.00M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $68.00M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $32.00M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $105.77M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $58.40M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $33.14M | Mar 13, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.34B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $14.14B | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $18.43B | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $25.86B | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $24.67B | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $7.34B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $1.59B | Feb 26, 2021 |
| FY2019 | Jan 1, 2019 | $2.02B | Feb 27, 2020 |
| FY2019 | Dec 31, 2018 | $1.96B | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $1.08B | Mar 13, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.69B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $3.24B | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $4.57B | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $6.74B | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $10.52B | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $4.78B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $414.61M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $431.91M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $459.19M | Mar 13, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.65B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $10.90B | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $13.85B | Feb 20, 2026 |
| FY2025 | Dec 31, 2022 | $19.12B | Feb 20, 2026 |
| FY2024 | Dec 31, 2021 | $14.15B | Feb 21, 2025 |
| FY2023 | Dec 31, 2020 | $2.56B | Feb 23, 2024 |
| FY2022 | Dec 31, 2019 | $1.18B | Feb 24, 2023 |
| FY2021 | Dec 31, 2018 | $1.53B | Feb 25, 2022 |
| FY2020 | Dec 31, 2017 | ($551.37M) | Feb 26, 2021 |
| FY2019 | Dec 31, 2016 | ($334.81M) | Feb 27, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $52.00M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $52.00M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $52.00M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Feb 23, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.22B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $10.05B | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $13.61B | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $18.32B | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $9.96B | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | ($2.24B) | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | ($1.50B) | Feb 26, 2021 |
| FY2019 | Jan 1, 2019 | ($982.43M) | Feb 27, 2020 |
| FY2019 | Dec 31, 2018 | ($1.01B) | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | ($621.89M) | Mar 13, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.60B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $1.93B | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $2.91B | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $3.21B | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $6.85B | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $2.62B | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $236.00M | Feb 25, 2022 |
| FY2019 | Dec 31, 2018 | $658.36M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $134.86M | Mar 13, 2019 |
| FY2018 | Dec 31, 2016 | $50.08M | Mar 13, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (7) | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | (9) | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | (12) | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | 21 | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | 30 | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Feb 25, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (7) | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | (9) | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | (12) | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | 20 | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | 28 | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Feb 25, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 394.00M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | 386.00M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | 382.00M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | 385.00M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | 403.00M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | 399.00M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | 336.54M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | 328.80M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | 65.21M | Mar 13, 2019 |